Cited by 7,267COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory Support and Mechanisms

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Remdesivir for the Treatment of Covid-19 — Final Report

Open access

Beigel, John H., Tomashek, Kay M., Dodd, Lori E., Mehta, Aneesh K., Zingman, Barry S., Kalil, Andre C., Hohmann, Elizabeth, Chu, Helen Y., Luetkemeyer, Annie, Kline, Susan, Lopez de Castilla, Diego, Finberg, Robert W., Dierberg, Kerry, Tapson, Victor, Hsieh, Lanny, Patterson, Thomas F., Paredes, Roger, Sweeney, Daniel A., Short, William R., Touloumi, Giota, Lye, David Chien, Ohmagari, Norio, Oh, Myoung-don, Ruiz-Palacios, Guillermo M., Benfield, Thomas, Fätkenheuer, Gerd, Kortepeter, Mark G., Atmar, Robert L., Creech, C. Buddy, Lundgren, Jens, Babiker, Abdel G., Pett, Sarah, Neaton, James D., Burgess, Timothy H., Bonnett, Tyler, Green, Michelle, Makowski, Mat, Osinusi, Anu, Nayak, Seema, Lane, H. Clifford·2020·New England Journal of Medicine

DOI 10.1056/nejmoa2007764PMC PMC7262788

Open this paper in CoChat — free account

Abstract

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2007764

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,258 · cited 4×
“The trial site in South Korea received funding from the Seoul National University Hospital.”
Influential
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,442
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Sheahan, T. P., Sims, A. M., Leist, S. R., Schäfer, A., Won, J. J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D. M., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,757
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575 · cited 3×
“There were 60 trial sites and 13 subsites in the United States (45 sites), Denmark (8), the United Kingdom (5), Greece (4), Germany (3), Korea (2), Mexico (2), Spain (2), Japan (1), and Singapore (1).”
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Agostini, M. L., Andres, E. L., Sims, A. M., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,418
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
Spinner, C. D., Gottlieb, R., Criner, G. J., Arribas, J. R., Cattelan, A. M., Soriano, À., Ogbuagu, O. E., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,234
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D. P., Cihlář, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 888

Flagged first, then by citations

Show all 22 references

Sorted by citations

Items 101–200 of 1,018

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
Hoffmann, M., Hofmann-Winkler, H., Smith, J. C., Krüger, N., Arora, P., Sørensen, L. K., Søgaard, O. S., Hasselstrøm, J. B., Winkler, M., Hempel, T., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103255 · Cited by 397
Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach
Sperotto, F., Friedman, K. G., Son, M. B. F., VanderPluym, C. J., Newburger, J. W., & Dionne, A. (2020) · European Journal of Pediatrics · doi:10.1007/s00431-020-03766-6 · Cited by 384
COVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 425
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
López‐Medina, E., López, P., Hurtado, I. C., Davalos, D. M., Ramírez, Ó., Martínez, E., Sánchez, J. A. D., Oñate, J., Chavarriaga, H., Herrera, S. V., et al. (2021) · JAMA · doi:10.1001/jama.2021.3071 · Cited by 378
Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses
Song, W., Hui, C., Hull, J. H., Birring, S. S., McGarvey, L. P., Mazzone, S. B., & Chung, K. F. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00125-9 · Cited by 386
Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis
Lim, Z. J., Subramaniam, A., Reddy, M. P., Blecher, G., Kadam, U., Afroz, A., Billah, B., Ashwin, S., Kubicki, M. A., Bilotta, F., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202006-2405oc · Cited by 372
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani, O., Abbas, A., Abbas, F., Abbas, M. A., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00163-5 · Cited by 392
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
Piechotta, V., Chai, K. L., Valk, S. J., Doree, C. J., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So‐Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub2 · Cited by 372
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19
Lópes, R. D., Macedo, A. V. S., Silva, P. G. M. D. B. E., Moll-Bernardes, R. J., dos Santos, T. M., Barbosa, L. M., Feldman, A., Arruda, G., de Albuquerque, D. C., Camiletti, A. S., et al. (2021) · JAMA · doi:10.1001/jama.2020.25864 · Cited by 374
COVID-19: breaking down a global health crisis
Mallah, S. I., Ghorab, O. K. H. A., Al-Salmi, S., Abdellatif, O. S., Tharmaratnam, T., Iskandar, M. M. A., Sefen, J. A. N., Sidhu, P., Atallah, B., El-Lababidi, R. M., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00438-7 · Cited by 401
Redefining critical illness
Maslove, D. M., Tang, B. M. P., Shankar‐Hari, M., Lawler, P. R., Angus, D. C., Baillie, J. K., Baron, R. M., Bauer, M. W., Buchman, T. G., Calfee, C. S., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01843-x · Cited by 373
“…wellspring of evidence, suggesting that a patient in her condition was likely to benefit from corticosteroids 3 and interleukin-6 receptor antagonists 4,5 , but that treatments for milder disease – including remdesivir 6 and systemic anticoagulation 7 – were unlikely to provide significant benefit.”
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
Furtado, R. H. M., Berwanger, O. B., Fonseca, H. A. R., Corrêa, T. D., Ferraz, L. J. R., Lapa, M. G., Zampieri, F. G., Veiga, V. C., Azevedo, L. C. P., Rosa, R. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31862-6 · Cited by 360
Treatment for COVID-19: An overview
Stasi, C., Silvia, F., Voller, F., & Silvestri, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173644 · Cited by 385
Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact
MacLeod, M. A., Papi, A. A., Contoli, M., Beghé, B., Celli, B. R., Wedzicha, J. A., & Fabbri, L. M. (2021) · Respirology · doi:10.1111/resp.14041 · Cited by 392
Coronavirus breakthrough: dexamethasone is first drug shown to save lives
Ledford, H. K. (2020) · Nature · doi:10.1038/d41586-020-01824-5 · Cited by 356
Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia
Cruz, A. S., Mendes‐Frias, A., Oliveira, A. I., Dias, L., Matos, A. R., Carvalho, A., Capela, C., Pedrosa, J., Castro, A. G., & Silvestre, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613422 · Cited by 364
ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection
Karki, R., Lee, S., Mall, R., Nagakannan, P., Wang, Y., Sharma, B. R., Malireddi, R. K. S., Yang, D., Trifkovic, S., Steele, J. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo6294 · Cited by 349
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
Gharbharan, A., Jordans, C. C. E., GeurtsvanKessel, C. H., den Hollander, J. G., Karim, F., Mollema, F. P. N., Stalenhoef, J. E., Dofferhoff, A. S. M., Ludwig, I., Koster, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23469-2 · Cited by 351
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich‐Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi‐Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 356
Lung transplantation for patients with severe COVID-19
Bharat, A., Querrey, M., Markov, N. S., Kim, S., Kurihara, C., Garza-Castillon, R., Manerikar, A., Shilatifard, A., Tomic, R., Politanska, Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe4282 · Cited by 336
SARS-CoV-2 and the pandemic of COVID-19
Adil, M. T., Rahman, R., Whitelaw, D., Jain, V., Al‐Taan, O., Rashid, F., Munasinghe, A., & Jambulingam, P. S. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138386 · Cited by 338
Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial
Ader, F., Bouscambert‐Duchamp, M., Hites, M., Peiffer‐Smadja, N., Poissy, J., Belhadi, D., Diallo, A., Lê, M., Peytavin, G., Staub, T., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00485-0 · Cited by 337
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01744-7 · Cited by 335
Emerging treatment strategies for COVID-19 infection
Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I., Ψαλτοπούλου, Θ., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00671-y · Cited by 335
Structures of the SARS‐CoV‐2 nucleocapsid and their perspectives for drug design
Peng, Y., Du, N., Lei, Y., Dorje, S., Qi, J., Luo, T., Gao, G. F., & Song, H. (2020) · The EMBO Journal · doi:10.15252/embj.2020105938 · Cited by 320
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
Forman, R., Shah, S. S., Jeurissen, P., Jit, M., & Mossialos, E. A. (2021) · Health Policy · doi:10.1016/j.healthpol.2021.03.013 · Cited by 308
Systemic and organ-specific immune-related manifestations of COVID-19
Ramos‐Casals, M., Brito‐Zerón, P., & Mariette, X. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00608-z · Cited by 316
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
Davoudi-Monfared, E., Rahmani, H. R., Khalili, H., Hajiabdolbaghi, M., Salehi, M., Abbasian, L., Kazemzadeh, H., & Yekaninejad, M. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-20 · Cited by 309
An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies
Tsang, H. F., Chan, L., Cho, W. C. S., Yu, A. C.-S., Yim, A. K., Chan, A. K. C., Ng, L. P. W., Wong, Y. K. E., Pei, X. M., Li, M. J. W., et al. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1863146 · Cited by 313
Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
Mengist, H. M., Dilnessa, T., & Jin, T. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.622898 · Cited by 304
COVID-19 and Solid Organ Transplantation: A Review Article
Azzi, Y., Bartash, R. M., Scalea, J. R., Loarte-Campos, P., & Akalin, E. (2020) · Transplantation · doi:10.1097/tp.0000000000003523 · Cited by 308
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Boras, B. W., Jones, R., Anson, B. J., Arenson, D., Aschenbrenner, L. M., Bakowski, M. A., Beutler, N., Binder, J. J., Chen, E., Eng, H. F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26239-2 · Cited by 429
Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2
Xu, Z., Shi, D., Han, J.-B., Ling, Y., Jiang, X., Lu, X., Li, C., Gong, L., Ge, G., Zhang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01429-0 · Cited by 304
“Remdesivir, an intravenously administered RdRp inhibitor, could reduce recovery time by 5 days in hospitalized adults.(7) Although remdesivir could reduce virus titers in bronchoalveolar lavages in a SARS-CoV-2 infected rhesus macaque model, it didn’t reduce virus shedding.”
Background
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Butler, C., Dorward, J., Yu, L., Gbinigie, O. A., Hayward, G., Saville, B. R., van Hecke, O., Berry, N., Detry, M. A., Saunders, C. T., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00461-x · Cited by 306
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
Bastard, P., Orlova, E., Sozaeva, L., Lévy, R., James, A. E., Schmitt, M. M., Ochoa, S., Kareva, M., Rodina, Y. A., Gervais, A., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210554 · Cited by 305
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension
Zhang, L., Sun, Y., Zeng, H., Wang, Q., Jiang, X., Shang, W., Wu, Y., Li, S., Zhang, Y., Hao, Z., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00235-0 · Cited by 316
Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review
Bavishi, C., Bonow, R. O., Trivedi, V., Abbott, J. D., Messerli, F. H., & Bhatt, D. L. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.05.013 · Cited by 298
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., Wang, L., Griffiths, C., Brown, M. L., Scott, W. E., et al. (2022) · Nature · doi:10.1038/s41586-022-05594-0 · Cited by 299
Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence
Hartley, G. E., Edwards, E. S. J., Aui, P. M., Varese, N., Stojanovic, S., McMahon, J., Peleg, A. Y., Boo, I., Drummer, H. E., Hogarth, P. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf8891 · Cited by 296
Remdesivir against COVID-19 and Other Viral Diseases
Malin, J. J., Suárez, I., Priesner, V., Fätkenheuer, G., & Rybniker, J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00162-20 · Cited by 296
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients
Hariharan, A., Hakeem, A. R., Radhakrishnan, S., Reddy, M. S., & Rela, M. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00773-9 · Cited by 300
Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis
Bertolini, A., van de Peppel, I. P., Bodewes, F. A. J. A., Moshage, H. J., Fantin, A., Farinati, F., Fiorotto, R., Jonker, J. W., Strazzabosco, M., Verkade, H. J., et al. (2020) · Hepatology · doi:10.1002/hep.31480 · Cited by 295
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
Bramante, C. T., Ingraham, N. E., Murray, T. A., Marmor, S., Hovertsen, S., Gronski, J., McNeil, C., Feng, R., Guzman, G., Abdelwahab, N., et al. (2020) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(20)30033-7 · Cited by 285
Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis
Tan, B. K., Mainbourg, S., Friggeri, A., Bertoletti, L., Douplat, M., Dargaud, Y. G., Grangé, C., Lobbes, H., Provencher, S., & Lega, J. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-215383 · Cited by 293
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence
Rahman, S., Montero, M. T. V., Rowe, K., Kirton, R., & Kunik, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1902303 · Cited by 315
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Yu, L., Bafadhel, M., Dorward, J., Hayward, G., Saville, B. R., Gbinigie, O. A., van Hecke, O., Ogburn, E., Evans, P. H., Thomas, N. P. B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01744-x · Cited by 291
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Drożdżal, S., Rosik, J., Lechowicz, K., Machaj, F., Szostak, B., Przybyciński, J., Lorzadeh, S., Kotfis, K., Ghavami, S., & Łoś, M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100794 · Cited by 301
Remdesivir: First Approval
Lamb, Y. N. (2020) · Drugs · doi:10.1007/s40265-020-01378-w · Cited by 287
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells
Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., & Fukushi, S. (2020) · Journal of Virology · doi:10.1128/jvi.01648-20 · Cited by 384
Respiratory Virus Infections: Understanding COVID-19
Subbarao, K., & Mahanty, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.004 · Cited by 287
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Drayman, N., DeMarco, J. K., Jones, K. A., Azizi, S., Froggatt, H. M., Tan, K., Maltseva, N., Chen, S., Nicolaescu, V. I., Dvorkin, S., et al. (2021) · Science · doi:10.1126/science.abg5827 · Cited by 280
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
Tharaux, P., Pialoux, G., Pavot, A., Mariette, X., Hermine, O., Resche‐Rigon, M., Porcher, R., Ravaud, P., Bureau, S., Dougados, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30556-7 · Cited by 295
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
Trougakos, I. P., Stamatelopoulos, K. S., Terpos, E., Tsitsilonis, O., Aivalioti, E., Paraskevis, D. N., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-020-00703-5 · Cited by 305
COVID-19: A review of therapeutic strategies and vaccine candidates
Izda, V., Jeffries, M. A., & Sawalha, A. H. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108634 · Cited by 292
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity
Zhou, S., Butler‐Laporte, G., Nakanishi, T., Morrison, D., Afilalo, J., Afilalo, M., Laurent, L., Pietzner, M., Kerrison, N. D., Zhao, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01281-1 · Cited by 268
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
Glasgow, A., Glasgow, J., Limonta, D., Solomon, P., Lui, I., Zhang, Y., Nix, M. A., Rettko, N. J., Zha, S., Yamin, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016093117 · Cited by 251
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
Drucker, D. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.016 · Cited by 272
Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
Maghbooli, Z., Sahraian, M. A., Ebrahimi, M., Pazoki, M., Kafan, S., Tabriz, H. M., Hadadi, A., Montazeri, M., Nasiri, M., Shirvani, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239799 · Cited by 287
Retracted
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19Preprint
Sekine, T., Perez‐Potti, A., Rivera‐Ballesteros, O., Strålin, K., Gorin, J., Olsson, A., Llewellyn‐Lacey, S., Kamal, H., Bogdanović, G., Muschiol, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.174888 · Cited by 272
Blockchain and AI-Based Solutions to Combat Coronavirus (COVID-19)-Like Epidemics: A Survey
Nguyen, D. C., Ding, M., Pathirana, P. N., & Seneviratne, A. (2021) · IEEE Access · doi:10.1109/access.2021.3093633 · Cited by 286
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Copaescu, A. M., Smibert, O. C., Gibson, A., Phillips, E. J., & Trubiano, J. A. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.001 · Cited by 263
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Saraboji, K. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 278
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
Humeniuk, R., Mathias, A. A., Cao, H., Osinusi, A. O., Shen, G., Chng, E., Ling, J. R., Vu, A., & German, P. (2020) · Clinical and Translational Science · doi:10.1111/cts.12840 · Cited by 259
SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery
Mulay, A., Konda, B. M., Garcia, G., Yao, C., Beil, S., Villalba, J. M., Koziol, C., Sen, C., Purkayastha, A., Kolls, J. K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109055 · Cited by 262
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics
Forchette, L., Sebastian, W., & Liu, T. (2021) · Current Medical Science · doi:10.1007/s11596-021-2395-1 · Cited by 275
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Lagier, J., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud‐Gatineau, A., Honoré, S., Gaubert, J., Fournier, P., Tissot‐Dupont, H., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101791 · Cited by 257
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities
Cannalire, R., Cerchia, C., Beccari, A. R., Leva, F. S. D., & Summa, V. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01140 · Cited by 261
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases
Meganck, R. M., & Baric, R. S. (2021) · Nature Medicine · doi:10.1038/s41591-021-01282-0 · Cited by 264
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
Stevens, L. J., Pruijssers, A. J. P., Lee, H. W., Gordon, C. J., Tchesnokov, E. P., Gribble, J., George, A. S., Hughes, T. M., Lu, X., Li, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo0718 · Cited by 249
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial
Kosiborod, M. N., Esterline, R., Furtado, R. H. M., Oscarsson, J., Gasparyan, S. B., Koch, G. G., Martinez, F., Mukhtar, O., Verma, S., Chopra, V., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00180-7 · Cited by 243
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
Lescure, F.-X., Honda, H., Fowler, R., Lazar, J. S., Shi, G., Wung, P. K., Patel, N. R., HAGINO, O. R., Bazzalo, I. J., Casas, M. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00099-0 · Cited by 259
Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19
Jorgensen, S. C. J., Kebriaei, R., & Dresser, L. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2429 · Cited by 246
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study
Lebreton, G., Schmidt, M., Ponnaiah, M., Folliguet, T. A., Para, M., Guihaire, J., Lansac, E., Sage, É., Cholley, B., Mégarbane, B., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00096-5 · Cited by 244
Azithromycin in the treatment of COVID-19: a review
Echeverría-Esnal, D., Martín‐Ontiyuelo, C., Navarrete-Rouco, M. E., de Antonio-Cuscó, M., Ferrández, O., Horcajada, J. P., & Grau, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1813024 · Cited by 257
Mechanisms of Stroke in COVID-19
Spence, J. D., de Freitas, G. R., Pettigrew, L. C., Ay, H., Liebeskind, D. S., Kase, C. S., Brutto, Ó. H. D., Hankey, G. J., & Venketasubramanian, N. (2020) · Cerebrovascular Diseases · doi:10.1159/000509581 · Cited by 248
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Sparks, J. A., Wallace, Z. S., Seet, A. M., Gianfrancesco, M. A., Izadi, Z., Hyrich, K. L., Strangfeld, A., Gossec, L., Carmona, L., Mateus, E. F., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220418 · Cited by 238
The development of COVID-19 treatment
Yuan, Y., Jiao, B., Qu, L., Yang, D., & Liu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125246 · Cited by 271
“The recovery time of adults hospitalized with COVID-19 and lower respiratory tract infection is shortened after receiving remdesivir treatment (47).”
Background
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
Rentsch, C. T., Beckman, J. A., Tomlinson, L. A., Gellad, W. F., Alcorn, C., Kidwai‐Khan, F., Skanderson, M., Brittain, E. L., King, J. T., Ho, Y.-L. A., et al. (2021) · BMJ · doi:10.1136/bmj.n311 · Cited by 240
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
Feld, J. J., Kandel, C. E., Biondi, M. J., Kozak, R. A., Zahoor, M. A., Lemieux, C., Borgia, S. M., Boggild, A. K., Powis, J. E., McCready, J., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30566-x · Cited by 239
Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19
Gaziano, L., Giambartolomei, C., Pereira, A. C., Gaulton, A., Posner, D. C., Swanson, S. A., Ho, Y.-L. A., Iyengar, S. K., Kosik, N., Vujković, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01310-z · Cited by 231
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity
Shen, Z., Ratia, K. M., Cooper, L. M., Kong, D., Lee, H., Kwon, Y., Li, Y., Alqarni, S., Huang, F., Dubrovskyi, O., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01307 · Cited by 237
Improving survival of critical care patients with coronavirus disease 2019 in England: a national cohort study, March to June 2020
Dennis, J. M., McGovern, A. P., Vollmer, S. J., & Mateen, B. A. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004747 · Cited by 214
Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19
van der Wijst, M. G. P., Vazquez, S. E., Hartoularos, G. C., Bastard, P., Grant, T., Bueno, R., Lee, D. S., Greenland, J. R., Sun, Y., Perez, R. K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh2624 · Cited by 226
Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications
Iwasaki, M., Saito, J., Zhao, H., Sakamoto, A., Hirota, K., & Ma, D. (2020) · Inflammation · doi:10.1007/s10753-020-01337-3 · Cited by 234
Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
Salazar, E., Christensen, P. A., Graviss, E. A., Nguyen, D. T., Castillo, B., Chen, J., Lopez, B. V., Eagar, T. N., Yi, X., Zhao, P., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.08.001 · Cited by 231
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
Dittmar, M., Lee, J. S., Whig, K., Segrist, E., Li, M., Kamalia, B., Castellana, L., Ayyanathan, K., Cardenas‐Diaz, F. L., Morrisey, E. E., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108959 · Cited by 230
Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries
Bharat, A., Machuca, T., Querrey, M., Kurihara, C., Garza‐Castillon, R., Kim, S., Manerikar, A. J., Peláez, A., Pipkin, M., Shahmohammadi, A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00077-1 · Cited by 233
Trends in COVID-19 risk-adjusted mortality rates
Horwitz, L. I., Jones, S. A., Cerfolio, R. J., Francois, F., Greco, J., Rudy, B., & Petrilli, C. M. (2021) · Journal of Hospital Medicine · doi:10.12788/jhm.3552 · Cited by 229
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2Preprint
Clausen, T. M., Sandoval, D. R., Spliid, C. B., Pihl, J., Painter, C. D., Thacker, B. E., Glass, C. A., Narayanan, A., Majowicz, S. A., Yang, Z., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.14.201616 · Cited by 229
Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters
Kuroda, K., Li, C., Dhangar, K., & Kumar, M. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.145740 · Cited by 228
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial
Soin, A. S., Kumar, K., Choudhary, N. S., Sharma, P., Mehta, Y. B., Kataria, S., Govil, D., Deswal, V., Chaudhry, D., Singh, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00081-3 · Cited by 232
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Zhou, Y., Gammeltoft, K. A., Ryberg, L. A., Pham, L. V., Tjørnelund, H. D., Binderup, A., Hernandez, C. R. D., Fernandez-Antunez, C., Offersgaard, A., Fahnøe, U., et al. (2022) · Science Advances · doi:10.1126/sciadv.add7197 · Cited by 227
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19
Jorgensen, S. C. J., Tse, C. L. Y., Burry, L. D., & Dresser, L. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2438 · Cited by 233
Biomimetic Human Disease Model of SARS‐CoV‐2‐Induced Lung Injury and Immune Responses on Organ Chip System
Zhang, M., Wang, P., Luo, R., Wang, Y., Li, Z., Guo, Y., Yao, Y., Li, M., Tao, T., Chen, W., et al. (2021) · Advanced Science · doi:10.1002/advs.202002928 · Cited by 236
Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
Baggen, J., Persoons, L., Vanstreels, E., Jansen, S., Looveren, D. V., Boeckx, B., Geudens, V., Man, J. D., Jochmans, D., Wauters, J., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00805-2 · Cited by 215
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
Shapira, T., Monreal, I. A., Dion, S. P., Buchholz, D. W., Imbiakha, B., Olmstead, A. D., Jager, M. C., Désilets, A., Gao, G., Martins, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04661-w · Cited by 248
Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome
Sawalha, K., Abozenah, M., Kadado, A. J., Battisha, A., Al-Akchar, M., Salerno, C., Hernandez-Montfort, J., & Islam, A. M. (2021) · Cardiovascular Revascularization Medicine · doi:10.1016/j.carrev.2020.08.028 · Cited by 217
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Chen, P., Söderdahl, G., Österborg, A., Smith, C. I. E., Wullimann, D. J., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103705 · Cited by 224
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Xie, X., Muruato, A. E., Zhang, X., Lokugamage, K. G., Fontes-Garfias, C. R., Zou, J., Liu, J., Ren, P., Balakrishnan, M., Cihlář, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19055-7 · Cited by 216

Authors: Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., Lye, D. C., Ohmagari, N., Oh, M.-D., Ruiz-Palacios, G. M., Benfield, T., Fätkenheuer, G., Kortepeter, M. G., Atmar, R. L., Creech, C. B., Lundgren, J., Babiker, A. G., Pett, S., Neaton, J. D., Burgess, T. H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S., & Lane, H. C.
Affiliations: National Institutes of Health (US)
From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) — all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical...
Corresponding author: Beigel, John H.
ORCID: Beigel, John H.
Dodd, Lori E.
Mehta, Aneesh K.
Zingman, Barry S.
Kalil, Andre C.
Hohmann, Elizabeth
Chu, Helen Y.
Luetkemeyer, Annie
Kline, Susan
Finberg, Robert W.
Dierberg, Kerry
Tapson, Victor
Patterson, Thomas F.
Paredes, Roger
Short, William R.
Touloumi, Giota
Lye, David Chien
Ohmagari, Norio
Oh, Myoung-don
Ruiz-Palacios, Guillermo M.
Benfield, Thomas
Fätkenheuer, Gerd
Atmar, Robert L.
Creech, C. Buddy
Lundgren, Jens
Babiker, Abdel G.
Pett, Sarah
Neaton, James D.
Burgess, Timothy H.
Bonnett, Tyler
Makowski, Mat
Nayak, Seema
Lane, H. Clifford
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-11-05
Volume: 383
Issue: 19
Pages: 1813-1826
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2007764
PMC: PMC7262788
OpenAlex: W3027630905
Cited by: 7,267
References: 22
Citations by year: 2026: 146 · 2025: 324 · 2024: 518 · 2023: 901 · 2022: 1447 · 2021: 2475 · 2020: 1451
FWCI: 206.47
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
Figshare (submittedVersion, cc-by)
Sussex Research Online (University of Sussex) (submittedVersion)
VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
eScholarship@McGill (McGill) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
Funders: Division of Intramural Research, National Institute of Allergy and Infectious Diseases
National Cancer Institute (HHSN261200800001E, HHSN261201500003I)
National Institute of Allergy and Infectious Diseases (UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148575, UM1AI148576, UM1AI148684, UM1AI148685, UM1AI148689)
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
Keywords: remdesivir, COVID-19 pandemic, SARS-CoV-2, antiviral therapy, hospitalized patients, lower respiratory tract infection, time to recovery, mortality, serious adverse events, clinical improvement, treatment efficacy, SARS-CoV-2 RNA load, viral load reduction, disease severity, prognostic factors, prognostic score
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adenosine Monophosphate, Adult, Aged, Alanine, Antiviral Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Oxygen Inhalation Therapy, Pneumonia, Viral, Respiration, Artificial, Time Factors, Extracorporeal Membrane Oxygenation, Coronavirus Infections, Kaplan-Meier Estimate, Young Adult, Pandemics, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Remdesivir for the Treatment of Covid-19 — Final Report

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks